neurology
Movement disorders

Omaveloxolone show promise in Friedreich’s ataxia

A novel therapy omaveloxolone could potentially be beneficial for patients with Friedreich’s ataxia, according to results from a phase 2 trial that involved Australian centres. The drug, which is a small molecule Nrf2 activator resulted in significantly improved neurological function compared to placebo in a one year randomised controlled trial involving 103 patients with Friedreich’s ataxia. ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic